Michael Garson Email & Phone Number

• Responsible for sales and training for Oncologists in the Mid-Atlantic region for Breast Cancer, Prostate Cancer and Surgical Navigation Products• Responsible for selling Fracture Care Devices, Upper and Lower Extremity Implants & Wound Care portfolio• Coordinated clinical education and sales to Interventional Cardiologists for AI medical device for rapid rule out of Coronary Artery Disease• Manage territory key accounts for the sales productivity and profitability of the territory.• Negotiate Hospital, IDN and Organizational contracts for volume, exclusivity, P&T and Formulary Acceptance• Buy and Bill, Reimbursement and HUB services expertise • Achieved and exceeded sales quota consistently, top performer in division• Developed, implemented and utilized business action plans to maximize sales performance• C-Arm Diagnostic Imaging sales to ASC’s, IDN’s and Group Practices. Exceeded quota sales of $800,000+

(Company dissolved division)• Account Management for Surgical, ASC, Hospital and Clinic procedures • Responsible for the successful launch and promotion of surgical implant Dextenza within the Ophthalmology community• Facilitate clinical training of Dextenza to Ophthalmology, Cataract, Retina and Glaucoma specialists • Assist accounts with becoming proficient with the reimbursement process to position products for adoption and usage in a Buy and Bill environment• Act as a liaison to help accounts understand and manage local payer reimbursement policies and market access • Successfully negotiated with P&T and VAC; Value Analysis Committee for Formulary win of Dextenza• Negotiated, Presented and Converted Dextenza contract to The Johns Hopkins Health System

• Responsible for sales and training for Oncologists, Hematologists and Pharmacists in the Mid-Atlantic region for Breast Cancer, Gastric Cancers and Febrile Neutropenia products• Manage territory key accounts and accountable for the sales productivity and profitability of the territory• Responsible for selling injectable Biosimilar Oncology products to all Oncologists and Pharmacy Directors in the Mid-Atlantic including Hospitals IDN’s and Infusion Centers• Buy and Bill, Market Access, HUB services and Reimbursement expertise• Achieved and exceeded sales quota consistently, top 10% performer in division• Assisted in contract negotiations for Hospitals, IDN’s and Cancer Centers with P&T Committee and VAC Committee to convert and close business for Formulary wins• Converted Inova Hospital System and The Johns Hopkins Health System

(Boston Scientific acquired company and position was eliminated)• Sales and Account Management for a Portfolio of minimally invasive Disruptive Capital Equipment and Medical Devices for Liver Directed Therapy• Partnered with Transplant Specialists, Imaging Team, Rare Disease Oncologists, Interventional Oncologists, Interventional Radiologists, GI Specialists and Oncologists • Develop, implement and lead strategic marketing plans with referring physicians to attain corporate goals• Establish relationships with KOL’s and develop new KOL’s in targeted accounts • Deliver C-Suite presentations and Cost/Benefit analysis proposals• Responsible for implementation and execution of National, Regional and Local Medical Education Programs in targeted accounts • Develop innovative Peer to Peer programs and Strategic Programs• Ranked Number 1 in the Nation FY18 with sales greater than $5.1 million• Increased sales $2.5 million to $5.1 million 104% increase, 2018• Achieved 113% of quota. Only Key Account Manager to meet and exceed Quota Attainment FY18• Greater than 100% of quota 7 out of 12 months for FY19 Sales (12 consecutive months of exceeding National Sales Average)• Converted 99% of competitor accounts over to BTG accounts

Mid Atlantic Region

• Develop and implement Oncology strategies to execute operations and marketing plans• Provide C-Suite presentations and ROI analysis • Focus on product positioning, market penetration and building a preference for SIR-Spheres Resin Microspheres in the Oncology community for a unique FDA approved Disruptive Targeted Medical Device for Liver Tumors and Rare Disease Oncology Tumors• Partnered with Transplant Team Specialists, Imaging and Radiology Teams, GI Specialists, Interventional Oncologists, Interventional Radiologists and Oncologists • Oversee Market Research Council Marketing Programs• Grew 2016 sales by 43% over previous year (311 vs 219)• Increased total sales $3.5 million to $5 million from 2015 to 2016• 100% to plan for 2017

Mid Atlantic Region

(Dissolved Oncology Franchise)• Responsible for sales of Gliadel, an Implantable Chemotherapy Medical Device • Launched Gliadel to Mid Atlantic Neurosurgical Specialists, Hospitalists, ED & Critical Care Clinicians• Ranked 5 out of 22 territories, 115% to quota for Gliadel• Successfully launched Nymalize, (oral nimodipine) treatment for subarachnoid hemorrhage to Hospitalists, ED and Critical Care Clinicians• Achieved 195% to quota during launch• Managed #1 Ranked Nymalize account in the country• Ranked 1 out of 22 territories for Nymalize• Achieved Formulary wins for Nymalize and Gliadel with P&T and VAC presentations with Pharmacy Directors